SUCCESS INDICATORS Sample Clauses

SUCCESS INDICATORS. Performance monitoring is carried out on the basis of success indicators and performance measurement throughout and after the funding phase. The results of performance measurement and evaluation (indicators and their values) will be part of the progress reporting to the European Commission. The following table, extracted from the DoW, provides a summarised view of the quantitative indicators adopted for the dissemination and networking activities, and a quantification of targets, against which the results can be measured over consecutive periods of 1 year. No WP Indicator Method of measurement / Resp. Expected Progress Year 1 Year 2 Year 3 Year 4 4 WP3 Network of common interest established Cooperation Agreements signed / PROMOTER 2 members 5 members 10 members 20 members 5 WP3 National working groups Working groups established in the partners home countries Preparator y meetings Invitation to the Open Source Workshop Invitation to the Experienc e workshop Invitation to the final conferen ce 6 WP3 Open Source Workshop Workshop held / HS - 20 participan ts - - 7 WP3 Experience Workshop Workshop held / SPK - - 30 participan ts - 8 WP4 Visibility of the PREFORMA website Google Analytics / PROMOTER 100 visitors 500 visitors 1,000 visitors 2,000 visitors 9 WP4 Final conference Participants to the conference / RA - - - 150
Sample 1
AutoNDA by SimpleDocs
SUCCESS INDICATORS. The City agrees to monitor the Project for three consecutive years following the completion of the Project and the City agrees to report the following information to Metro upon completion of the Project.
Sample 1
SUCCESS INDICATORS. Summative Application of:  Appropriately use language of instruction and framework vocabulary  The interdependence of dimensions/domains and indicators/components  The key ideas in each criteria/indicators/components and what evidence would look like/sound like  The essential aspects of the frameworkThe evidence for all aspects of the framework and ability to determine summative criterion level scores using that evidence. Districts should be creating plans to: Develop and sustain rater agreement. This includes summative scoring against a pre-determined standard. ICFFs/LCFFs (Instructional or Leadership Criteria and Framework Feedback Specialist): A team of Washington State practitioners who are trained by framework author designees to provide facilitation around Stage 1 and 2 on the specific instructional or leadership framework chosen by OSPI as the approved instructional or leadership frameworks. These practitioners applied and were selected by a state-level committee through a rigorous process. The ICFFs and LCFFs are not experts in the new evaluation law. They are gaining expertise around the frameworks by the framework authors as the foundational tool for the new evaluation systems for teachers and principals. If your district would like more information on the details of the new evaluation system please contact the TPEP office at OSPI. Teacher and Principal Evaluation, OSPI Xxxxxxxx Xxxxxx, TPEP, National Board, and BEST Director Xxxxxxxx.xxxxxx@x00.xx.xx Xxx Xxxxx, TPEP Director Xxx.xxxxx@x00.xx.xx  Where am I? (What are the performance goals based on a self-assessment of the rubrics?)  Where am I going? (How is my performance related to the rubrics?)  Where to next? (What actions do I need to take next to increase my performance?)
Sample 1
SUCCESS INDICATORS. The following table, extracted from the DoW, provides a summarised view of the quantitative indicators adopted for the dissemination and networking activities, and a quantification of targets, against which the results can be measured over the course of the project. Number of focus groups organised 3 - 3 focus groups will take place during the first 3 months of the project, in Valletta, Stockholm and Coventry. Total number of participants in focus groups across Europe 30 - Focus groups will involve citizen researchers with different areas of interest. Number of participants in the user needs workshop 20 - A public Workshop on user needs will be organised at month 4 in Valletta to discuss the intermediate results of WP2 with external experts. Number of attendees to the public presentation of the Roadmap - 20 A workshop is organised in Brussels, among selected representatives of the stakeholders in order to present the Roadmap and to kick-off the consultation activities. Number of attendees to the workshop for cultural heritage institutions - 20 A workshop is organised in Budapest for cultural heritage institutions to discuss the conditions for their cooperation with citizens. Number of organisations providing feedback on the draft Roadmap - 30 The CIVIC EPISTEMOLOGIES Roadmap is promoted online to relevant stakeholders in order to receive their feedback. Research programmes by national and international research bodies, which are identified as good candidates to become adopters of the recommendations produced by the project. - 3 Each partner will work in its own country to identify relevant programme(s). Total number of participants to the case studies meetings 20 - Case studies meetings will be organised in Coventry. Total number of participants to the pilot 20 The pilot will be organised in Western Ireland. Participants include teachers and students. Number of associations registered to the project’s website 5 15 A specific area of the website will be devoted to securing involvement of associations of citizens interested in the topics addressed by the project. Number of national and European projects contacted and who expressed interest in future cooperation 5 10 Ad-hoc agreements of cooperation will be established and signed with these projects. Website statistics page views: 30.000 visits: 2.000 per month page views: 50.000 visits: 4.000 per month Statistics will be monitored periodically and Search Engine Optimisation activities organised consequently....
Sample 1

Related to SUCCESS INDICATORS

  • Performance Indicators The HSP’s delivery of the Services will be measured by the following Indicators, Targets and where applicable Performance Standards. In the following table: INDICATOR CATEGORY INDICATOR P=Performance Indicator E=Explanatory Indicator M=Monitoring Indicator 2022/23 Organizational Health and Financial Indicators Debt Service Coverage Ratio (P) 1 ≥1 Total Margin (P) 0 ≥0 Coordination and Access Indicators Percent Resident Days – Long Stay (E) n/a n/a Wait Time from Home and Community Care Support Services (HCCSS) Determination of Eligibility to LTC Home Response (M) n/a n/a Long-Term Care Home Refusal Rate (E) n/a n/a Quality and Resident Safety Indicators Percentage of Residents Who Fell in the Last 30 days (M) n/a n/a Percentage of Residents Whose Pressure Ulcer Worsened (M) n/a n/a Percentage of Residents on Antipsychotics Without a Diagnosis of Psychosis (M) n/a n/a Percentage of Residents in Daily Physical Restraints (M) n/a n/a

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Commercialization Plan (a) Not later than three [***] after submission of Regulatory Filings for each Product in each country of the Territory, Licensee will provide to the JCC for review its initial Commercialization Plan for each Product for each country in the Territory. Such initial Commercialization Plan will describe Licensee’s plans for activities to be conducted for such Product for such country. Each Commercialization Plan shall include the details of obligations to be performed by Licensee to achieve the specific activities that are applicable to the stage of [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Commercialization (e.g., pre-launch, launch planning, launch, or post-launch) of the applicable Product during the time period covered by such Commercialization Plan and subsequent time periods. (b) Prior to the First Commercial Sale for such Product in such country, Licensee will provide to the JCC for review an updated Commercialization Plan for such Product for such country. Such updated Commercialization Plan will include, but not be limited to, Licensee’s updated plans for activities to be conducted for such Product for such country prior to launch as well as activities to be conducted in connection with such launch. (c) Promptly after each anniversary of the First Commercial Sale of such Product during the Term, Licensee will provide to the JCC for review updated Commercialization Plans for such Product for such country. Such further updated Commercialization Plan will include, but not be limited to, Licensee’s plans for Commercialization activities for such Product and such country for the twelve (12) month period following the date of delivery of such Commercialization Plan. No Commercialization Plan may be implemented by Licensee if [***]. Each Commercialization Plan shall be consistent with and shall not contradict the terms of this Agreement [***], and in the event of any inconsistency between the Commercialization Plan and this Agreement, the terms of this Agreement shall prevail. Notwithstanding the foregoing, if a [***], Licensee shall [***] and shall promptly [***].

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving (either itself or through the acts of a SUBLICENSEE) the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • For clarity the time allowances provided in clause 2.10 shall operate to reduce the maximum timetabled classroom teaching time specified in clause 4.2 of this agreement.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Milestones Subject to the provisions of the SGIP, the Parties shall agree on milestones for which each Party is responsible and list them in Attachment 4 of this Agreement. A Party’s obligations under this provision may be extended by agreement. If a Party anticipates that it will be unable to meet a milestone for any reason other than a Force Majeure event, it shall immediately notify the other Parties of the reason(s) for not meeting the milestone and (1) propose the earliest reasonable alternate date by which it can attain this and future milestones, and (2) requesting appropriate amendments to Attachment 4. The Party affected by the failure to meet a milestone shall not unreasonably withhold agreement to such an amendment unless it will suffer significant uncompensated economic or operational harm from the delay, (1) attainment of the same milestone has previously been delayed, or (2) it has reason to believe that the delay in meeting the milestone is intentional or unwarranted notwithstanding the circumstances explained by the Party proposing the amendment.

  • Licensed Product The term “Licensed Product” shall mean any product (a) the manufacture, use, importation, sale or offer for sale of which would, in the absence of the license granted by this Agreement, infringe a Valid Claim of any of the Licensed Patent Rights, or (b) that is comprised of, utilizes or incorporates Licensed Biological Materials, or (c) that is discovered, developed or made using a Licensed Process.

  • KEY PERFORMANCE INDICATORS 10.1 The Supplier shall at all times during the Framework Period comply with the Key Performance Indicators and achieve the KPI Targets set out in Part B of Framework Schedule 2 (Goods and/or Services and Key Performance Indicators).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!